Login Register Cart 0
General Review Article

他汀类药物在中风中的应用

卷 26, 期 33, 2019

页: [6174 - 6185] 页: 12

弟呕挨: 10.2174/0929867326666190620104539

价格: $65

摘要

背景：中风是现代社会中致死和致残的主要原因。他汀类药物是通过降低血脂和多效性药物减少心血管事件的有效药物。 目的：总结关于他汀类药物在中风预防和管理中作用的最新证据。 方法：叙述有关他汀类药物在卒中治疗中作用的最新证据。电子搜索MEDLINE，EMBASE和Cochrane数据库。 结果：在具有危险因素但没有确定的心血管疾病的患者中风的一级预防中，有效的他汀类药物（如阿托伐他汀和罗苏伐他汀）已显示出某些益处，但这种作用的临床相关性值得怀疑。在中风风险较高的人群中，例如已确定的冠心病患者，大多数相关研究表明他汀类药物在预防中风方面具有有益作用。同样，在先前有脑血管事件的患者中，他汀类药物对于预防复发事件有明显的益处。在初级预防研究中，他汀类药物的使用与颅内出血风险的增加无关。高剂量他汀类药物在先前有脑血管事件的患者中非致命性出血性中风的发生率可能会增加。服用他汀类药物时中风的患者不应停用他汀类药物。此外，在未接受他汀类药物的中风急性期服用他汀类药物的患者，其生存期更长，功能结局改善。相反，他汀类药物在接受溶栓治疗的急性缺血性中风患者中没有任何益处。 结论：他汀类药物治疗可预防缺血性中风，特别是在心血管疾病高风险和已确定的动脉粥样硬化疾病的患者中。脂质降低和多效性作用似乎都有助于这些作用。

关键词: 他汀类药物，中风，脑血管事件，缺血性中风，出血性中风，死亡率，动脉粥样硬化性疾病。

« Previous
[1]
http://www.who.int/mediacentre/factsheets/fs310/en/ assessed 3rd June. 2017.
[2]
Meschia, J.F.; Bushnell, C.; Boden-Albala, B.; Braun, L.T.; Bravata, D.M.; Chaturvedi, S.; Creager, M.A.; Eckel, R.H.; Elkind, M.S.; Fornage, M.; Goldstein, L.B.; Greenberg, S.M.; Horvath, S.E.; Iadecola, C.; Jauch, E.C.; Moore, W.S.; Wilson, J.A. American heart association stroke council council on cardiovascular and stroke nursing council on clinical cardiology council on functional genomics and translational biology council on hypertension. Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 2014, 45(12), 3754-3832.
[http://dx.doi.org/10.1161/STR.0000000000000046] [PMID: 25355838]
[3]
Mihaylova, B.; Emberson, J.; Blackwell, L.; Keech, A.; Simes, J.; Barnes, E.H.; Voysey, M.; Gray, A.; Collins, R.; Baigent, C. Cholesterol Treatment Trialists’ (CTT) Collaborators.The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet, 2012, 380(9841), 581-590.
[http://dx.doi.org/10.1016/S0140-6736(12)60367-5] [PMID: 22607822]
[4]
Hong, K.S.; Lee, J.S. Statins in acute ischemic stroke: a systematic review. J. Stroke, 2015, 17(3), 282-301.
[http://dx.doi.org/10.5853/jos.2015.17.3.282] [PMID: 26437994]
[5]
Blum, A. HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis. Biofactors, 2014, 40(3), 295-302.
[http://dx.doi.org/10.1002/biof.1157] [PMID: 25077301]
[6]
Cimino, M.; Gelosa, P.; Gianella, A.; Nobili, E.; Tremoli, E.; Sironi, L. Statins: multiple mechanisms of action in the ischemic brain. Neuroscientist, 2007, 13(3), 208-213.
[http://dx.doi.org/10.1177/1073858406297121] [PMID: 17519364]
[7]
Iso, H.; Jacobs, D.R., Jr; Wentworth, D.; Neaton, J.D.; Cohen, J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med., 1989, 320(14), 904-910.
[http://dx.doi.org/10.1056/NEJM198904063201405] [PMID: 2619783]
[8]
Shepherd, J.; Cobbe, S.M.; Ford, I.; Isles, C.G.; Lorimer, A.R.; MacFarlane, P.W.; McKillop, J.H.; Packard, C.J. West of Scotland Coronary Prevention Study Group.Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 1995, 333(20), 1301-1307.
[http://dx.doi.org/10.1056/NEJM199511163332001] [PMID: 7566020]
[9]
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA, 2002, 288(23), 2998-3007.
[http://dx.doi.org/10.1001/jama.288.23.2998] [PMID: 12479764]
[10]
Nakamura, H.; Arakawa, K.; Itakura, H.; Kitabatake, A.; Goto, Y.; Toyota, T.; Nakaya, N.; Nishimoto, S.; Muranaka, M.; Yamamoto, A.; Mizuno, K.; Ohashi, Y. MEGA Study Group.Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006, 368(9542), 1155-1163.
[http://dx.doi.org/10.1016/S0140-6736(06)69472-5] [PMID: 17011942]
[11]
Sever, P.S.; Dahlöf, B.; Poulter, N.R.; Wedel, H.; Beevers, G.; Caulfield, M.; Collins, R.; Kjeldsen, S.E.; Kristinsson, A.; McInnes, G.T.; Mehlsen, J.; Nieminen, M.; O’Brien, E.; Ostergren, J. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet, 2003, 361(9364), 1149-1158.
[http://dx.doi.org/10.1016/S0140-6736(03)12948-0] [PMID: 12686036]
[12]
Ridker, P.M.; Danielson, E.; Fonseca, F.A.; Genest, J.; Gotto, A.M., Jr; Kastelein, J.J.; Koenig, W.; Libby, P.; Lorenzatti, A.J.; MacFadyen, J.G.; Nordestgaard, B.G.; Shepherd, J.; Willerson, J.T.; Glynn, R.J. JUPITER Study Group.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med., 2008, 359(21), 2195-2207.
[http://dx.doi.org/10.1056/NEJMoa0807646] [PMID: 18997196]
[13]
Yebyo, H.G.; Aschmann, H.E.; Kaufmann, M.; Puhan, M.A. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Am. Heart J., 2019, 210, 18-28.
[http://dx.doi.org/10.1016/j.ahj.2018.12.007] [PMID: 30716508]
[14]
Sacks, F.M.; Pfeffer, M.A.; Moye, L.A.; Rouleau, J.L.; Rutherford, J.D.; Cole, T.G.; Brown, L.; Warnica, J.W.; Arnold, J.M.; Wun, C.C.; Davis, B.R.; Braunwald, E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N. Engl. J. Med., 1996, 335(14), 1001-1009.
[http://dx.doi.org/10.1056/NEJM199610033351401] [PMID: 8801446]
[15]
White, H.D.; Simes, R.J.; Anderson, N.E.; Hankey, G.J.; Watson, J.D.; Hunt, D.; Colquhoun, D.M.; Glasziou, P.; MacMahon, S.; Kirby, A.C.; West, M.J.; Tonkin, A.M. Pravastatin therapy and the risk of stroke. N. Engl. J. Med., 2000, 343(5), 317-326.
[http://dx.doi.org/10.1056/NEJM200008033430502] [PMID: 10922421]
[16]
The Scandinavian Simvastatin Survival Study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet, 1994, 344, 1383-1389.
[PMID: 7968073]
[17]
Athyros, V.G.; Papageorgiou, A.A.; Mercouris, B.R.; Athyrou, V.V.; Symeonidis, A.N.; Basayannis, E.O.; Demitriadis, D.S.; Kontopoulos, A.G. Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr. Med. Res. Opin., 2002, 18(4), 220-228.
[http://dx.doi.org/10.1185/030079902125000787] [PMID: 12201623]
[18]
de Lemos, J.A.; Blazing, M.A.; Wiviott, S.D.; Lewis, E.F.; Fox, K.A.; White, H.D.; Rouleau, J.L.; Pedersen, T.R.; Gardner, L.H.; Mukherjee, R.; Ramsey, K.E.; Palmisano, J.; Bilheimer, D.W.; Pfeffer, M.A.; Califf, R.M.; Braunwald, E. Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA, 2004, 292(11), 1307-1316.
[http://dx.doi.org/10.1001/jama.292.11.1307] [PMID: 15337732]
[19]
Koren, M.J.; Hunninghake, D.B. ALLIANCE Investigators.Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J. Am. Coll. Cardiol., 2004, 44(9), 1772-1779.
[http://dx.doi.org/10.1016/j.jacc.2004.07.053] [PMID: 15519006]
[20]
Corvol, J.C.; Bouzamondo, A.; Sirol, M.; Hulot, J.S.; Sanchez, P.; Lechat, P. Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials. Arch. Intern. Med., 2003, 163(6), 669-676.
[http://dx.doi.org/10.1001/archinte.163.6.669] [PMID: 12639199]
[21]
O’Regan, C.; Wu, P.; Arora, P.; Perri, D.; Mills, E.J. Statin therapy in stroke prevention: a meta-analysis involving 121,000 patients. Am. J. Med., 2008, 121(1), 24-33.
[http://dx.doi.org/10.1016/j.amjmed.2007.06.033] [PMID: 18187070]
[22]
Amarenco, P.; Bogousslavsky, J.; Callahan, A., III; Goldstein, L.B.; Hennerici, M.; Rudolph, A.E.; Sillesen, H.; Simunovic, L.; Szarek, M.; Welch, K.M.; Zivin, J.A. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators.High-dose atorvastatin after stroke or transient ischemic attack. N. Engl. J. Med., 2006, 355(6), 549-559.
[http://dx.doi.org/10.1056/NEJMoa061894] [PMID: 16899775]
[23]
Collins, R.; Armitage, J.; Parish, S.; Sleight, P.; Peto, R. Heart Protection Study Collaborative Group.Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet, 2004, 363(9411), 757-767.
[http://dx.doi.org/10.1016/S0140-6736(04)15690-0] [PMID: 15016485]
[24]
Hosomi, N.; Nagai, Y.; Kohriyama, T.; Ohtsuki, T.; Aoki, S.; Nezu, T.; Maruyama, H.; Sunami, N.; Yokota, C.; Kitagawa, K.; Terayama, Y.; Takagi, M.; Ibayashi, S.; Nakamura, M.; Origasa, H.; Fukushima, M.; Mori, E.; Minematsu, K.; Uchiyama, S.; Shinohara, Y.; Yamaguchi, T.; Matsumoto, M. J-STARS Collaborators. J-STARS Collaborators. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A multicenter, randomized, open-label, parallel-group study. EBioMedicine, 2015, 2(9), 1071-1078.
[http://dx.doi.org/10.1016/j.ebiom.2015.08.006] [PMID: 26501105]
[25]
Hosomi, N.; Kitagawa, K.; Nagai, Y.; Nakagawa, Y.; Aoki, S.; Nezu, T.; Kagimura, T.; Maruyama, H.; Origasa, H.; Minematsu, K.; Uchiyama, S.; Matsumoto, M. J-STARS Collaborators. J-STARS Collaborators. Desirable low-density lipoprotein cholesterol levels for preventing stroke recurrence: a post hoc analysis of the J-STARS Study (Japan Statin Treatment Against Recurrent Stroke). Stroke, 2018, 49(4), 865-871.
[http://dx.doi.org/10.1161/STROKEAHA.117.018870] [PMID: 29511130]
[26]
Hosomi, N.; Nagai, Y.; Kitagawa, K.; Nakagawa, Y.; Aoki, S.; Nezu, T.; Kagimura, T.; Maruyama, H.; Origasa, H.; Minematsu, K.; Uchiyama, S.; Matsumoto, M. J-STARS collaborators. J-STARS collaborators. Pravastatin reduces the risk of atherothrombotic stroke when administered within six months of an initial stroke event. J. Atheroscler. Thromb., 2018, 25(3), 262-268.
[http://dx.doi.org/10.5551/jat.40196] [PMID: 28924103]
[27]
Tramacere, I.; Boncoraglio, G.B.; Banzi, R.; Del Giovane, C.; Kwag, K.H.; Squizzato, A.; Moja, L. Comparison of statins for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis. BMC Med., 2019, 17(1), 67.
[http://dx.doi.org/10.1186/s12916-019-1298-5] [PMID: 30914063]
[28]
Antoniou, T.; Macdonald, E.M.; Yao, Z.; Hollands, S.; Gomes, T.; Tadrous, M.; Mamdani, M.M.; Juurlink, D.N. Canadian Drug Safety and Effectiveness Research Network. Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. CMAJ, 2017, 189(1), E4-E10.
[http://dx.doi.org/10.1503/cmaj.160303] [PMID: 28246253]
[29]
Pandit, A.K.; Kumar, P.; Kumar, A.; Chakravarty, K.; Misra, S.; Prasad, K. High-dose statin therapy and risk of intracerebral hemorrhage: A meta-analysis. Acta Neurol. Scand., 2016, 134(1), 22-28.
[http://dx.doi.org/10.1111/ane.12540] [PMID: 26647879]
[30]
Ziff, O.J.; Banerjee, G.; Ambler, G.; Werring, D.J. Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry, 2019, 90(1), 75-83.
[http://dx.doi.org/10.1136/jnnp-2018-318483] [PMID: 30150320]
[31]
Åsberg, S.; Farahmand, B.; Henriksson, K.M.; Appelros, P. Statins as secondary preventives in patients with intracerebral hemorrhage. Int. J. Stroke, 2018.
[http://dx.doi.org/10.1177/1747493018816476] [PMID: 30484749]
[32]
Jung, M.; Lee, S. Effects of statin therapy on the risk of intracerebral hemorrhage in Korean patients with hyperlipidemia. Pharmacotherapy, 2019, 39(2), 129-139.
[http://dx.doi.org/10.1002/phar.2211] [PMID: 30585646]
[33]
Yi, X.; Han, Z.; Wang, C.; Zhou, Q.; Lin, J. Statin and aspirin pretreatment are associated with lower neurological deterioration and platelet activity in patients with acute ischemic stroke. J. Stroke Cerebrovasc. Dis., 2017, 26(2), 352-359.
[http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2016.09.030] [PMID: 27793535]
[34]
Safouris, A.; Katsanos, A.H.; Kerasnoudis, A.; Krogias, C.; Kinsella, J.A.; Sztajzel, R.; Lambadiari, V.; Deftereos, S.; Kargiotis, O.; Sharma, V.K.; Demchuk, A.M.; Saqqur, M.; McCabe, D.J.H.; Tsivgoulis, G. Statin pretreatment and microembolic signals in large artery atherosclerosis. Stroke, 2018, 49(8), 1992-1995.
[http://dx.doi.org/10.1161/STROKEAHA.118.021542] [PMID: 29991656]
[35]
Chen, X.; Zhuang, X.; Peng, Z.; Yang, H.; Chen, L.; Yang, Q. Intensive statin therapy for acute ischemic stroke to reduce the number of microemboli: a preliminary, randomized controlled study. Eur. Neurol., 2018, 80(3-4), 163-170.
[http://dx.doi.org/10.1159/000494989] [PMID: 30485853]
[36]
Elkind, M.S.; Sacco, R.L.; MacArthur, R.B.; Fink, D.J.; Peerschke, E.; Andrews, H.; Neils, G.; Stillman, J.; Corporan, T.; Leifer, D.; Cheung, K. The Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke. Int. J. Stroke, 2008, 3(3), 210-218.
[http://dx.doi.org/10.1111/j.1747-4949.2008.00200.x] [PMID: 18705902]
[37]
Lee, M.; Saver, J.L.; Wu, Y.L.; Tang, S.C.; Lee, J.D.; Rao, N.M.; Wang, H.H.; Jeng, J.S.; Lee, T.H.; Chen, P.C.; Ovbiagele, B. Utilization of statins beyond the initial period after stroke and 1-year risk of recurrent stroke. J. Am. Heart Assoc., 2017, 6(8)e005658
[http://dx.doi.org/10.1161/JAHA.117.005658] [PMID: 28768645]
[38]
Montaner, J.; Chacón, P.; Krupinski, J.; Rubio, F.; Millán, M.; Molina, C.A.; Hereu, P.; Quintana, M.; Alvarez-Sabín, J. Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur. J. Neurol., 2008, 15(1), 82-90.
[http://dx.doi.org/10.1111/j.1468-1331.2007.02015.x] [PMID: 18070096]
[39]
Ní Chróinín, D.; Callaly, E.L.; Duggan, J.; Merwick, Á.; Hannon, N.; Sheehan, Ó.; Marnane, M.; Horgan, G.; Williams, E.B.; Harris, D.; Kyne, L.; McCormack, P.M.; Moroney, J.; Grant, T.; Williams, D.; Daly, L.; Kelly, P.J. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke, 2011, 42(4), 1021-1029.
[http://dx.doi.org/10.1161/STROKEAHA.110.596734] [PMID: 21372311]
[40]
Heo, J.H.; Song, D.; Nam, H.S.; Kim, E.Y.; Kim, Y.D.; Lee, K.Y.; Lee, K.J.; Yoo, J.; Kim, Y.N.; Lee, B.C.; Yoon, B.W.; Kim, J.S. EUREKA Investigators.EUREKA Investigators. Effect and safety of rosuvastatin in acute ischemic stroke. J. Stroke, 2016, 18(1), 87-95.
[http://dx.doi.org/10.5853/jos.2015.01578] [PMID: 26846760]
[41]
Ní Chróinín, D.; Asplund, K.; Åsberg, S.; Callaly, E.; Cuadrado-Godia, E.; Díez-Tejedor, E.; Di Napoli, M.; Engelter, S.T.; Furie, K.L.; Giannopoulos, S.; Gotto, A.M., Jr; Hannon, N.; Jonsson, F.; Kapral, M.K.; Martí-Fàbregas, J.; Martínez-Sánchez, P.; Milionis, H.J.; Montaner, J.; Muscari, A.; Pikija, S.; Probstfield, J.; Rost, N.S.; Thrift, A.G.; Vemmos, K.; Kelly, P.J. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke, 2013, 44(2), 448-456.
[http://dx.doi.org/10.1161/STROKEAHA.112.668277] [PMID: 23287777]
[42]
Kotlęga, D.; Gołąb-Janowska, M.; Meller, A.; Bajer-Czajkowska, A.; Zembroń-Łacny, A.; Nowacki, P.; Banach, M. Beneficial effects of pre-stroke statins use in cardioembolic stroke patients with atrial fibrillation: a hospital-based retrospective analysis. Arch. Med. Sci., 2019, 15(2), 385-392.
[http://dx.doi.org/10.5114/aoms.2019.82925] [PMID: 30899291]
[43]
Montaner, J.; Bustamante, A.; García-Matas, S.; Martínez-Zabaleta, M.; Jiménez, C.; de la Torre, J.; Rubio, F.R.; Segura, T.; Masjuán, J.; Cánovas, D.; Freijo, M.; Delgado-Mederos, R.; Tejada, J.; Lago, A.; Bravo, Y.; Corbeto, N.; Giralt, D.; Vives-Pastor, B.; de Arce, A.; Moniche, F.; Delgado, P.; Ribó, M. STARS Investigators.STARS Investigators. Combination of thrombolysis and statins in acute stroke is safe: Results of the STARS randomized trial (stroke treatment with acute reperfusion and simvastatin). Stroke, 2016, 47(11), 2870-2873.
[http://dx.doi.org/10.1161/STROKEAHA.116.014600] [PMID: 27758944]
[44]
Clua-Espuny, J.L.; Abilleira, S.; Queralt-Tomas, L.; Gonzalez-Henares, A.; Gil-Guillen, V.; Muria-Subirats, E.; Ballesta-Ors, J. Gonzalez-Henares, A.; Gil-Guillen, V.; Muria-Subirats, E.; Ballesta-Ors, J. Long- term survival after stroke according to reperfusion therapy, cardiovascular therapy and gender. Cardiol. Res., 2019, 10(2), 89-97.
[http://dx.doi.org/10.14740/cr839] [PMID: 31019638]
[45]
Kang, H.J.; Bae, K.Y.; Kim, S.W.; Kim, J.T.; Park, M.S.; Cho, K.H.; Kim, J.M. Effects of interleukin-6, interleukin-18, and statin use, evaluated at acute stroke, on post-stroke depression during 1-year follow-up. Psychoneuroendocrinology, 2016, 72, 156-160.
[http://dx.doi.org/10.1016/j.psyneuen.2016.07.001] [PMID: 27428088]
[46]
Beckman, J.A.; Liao, J.K.; Hurley, S.; Garrett, L.A.; Chui, D.; Mitra, D.; Creager, M.A. Atorvastatin restores endothelial function in normocholesterolemic smokers independent of changes in low-density lipoprotein. Circ. Res., 2004, 95(2), 217-223.
[http://dx.doi.org/10.1161/01.RES.0000134628.96682.9b] [PMID: 15178637]
[47]
Oesterle, A.; Liao, J.K. The pleiotropic effects of statins - from coronary artery disease and stroke to atrial fibrillation and ventricular tachyarrhythmia. Curr. Vasc. Pharmacol., 2019, 17(3), 222-232.
[http://dx.doi.org/10.2174/1570161116666180817155058] [PMID: 30124154]
[48]
Vlachopoulos, C.; Aznaouridis, K.; Dagre, A.; Vasiliadou, C.; Masoura, C.; Stefanadi, E.; Skoumas, J.; Pitsavos, C.; Stefanadis, C. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. Eur. Heart J., 2007, 28(17), 2102-2109.
[http://dx.doi.org/10.1093/eurheartj/ehm247] [PMID: 17597050]

Rights & Permissions Print Cite
Article Metrics
65
9
© 2024 Bentham Science Publishers | Privacy Policy